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 INTRODUCTION 
 
Tumours of the ovary are common forms of neoplasms in women. The 
pathology of ovarian neoplsms is one of the most complex areas of gyneacology, 
because the ovary gives rise to the greater and larger variety of tumours than any 
other organ. While in other organs, tissue of origin is usually clear, tissue from 
which an ovarian tumour arises is often uncertain and most of the development of 
the presumptive tissue is often in disparity.(46) 
 
Ovarian tumours account for a considerable proportion of clinically 
important problems in  females and they are dangerous due to their silent growth. 
 
Worldwide, ovarian tumuor is the sixth most common tumor in women. In 
the western countries, ovarian carcinoma is the fifth most common malignancy 
and ranks fourth in cancer mortality. In U.S women, ovarian cancer accounts for 
5% of cancer deaths. In India, breast is the leading site of cancer, followed by 
cervix and ovary. In Chennai, ovarian cancer stands in the fourth position.(22,38,44) 
 
 
 About two thirds of ovarian tumours occur in women in the reproductive 
age group. In general the disease is most common in industrialized countries 
where parity is lower but there are notable exceptions such as Japan which has low 
parity and low rates of ovarian cancers.(8,22) 
 
          Evidence suggests that reproductive factors are important in ovarian cancer 
risk. Increase in parity and oral contraceptives offer protective effect for ovarian 
cancer. Some studies have demonstrated early menarche and late menopause as 
significant risk factors. High socioeconomic status contributes to increased ovarian 
cancer risk as a result of lower fertility rates in those women. Several risk factors 
have been identified, such as age at the birth of first child, breast feeding, weight, 
diet, talc, smoking, certain types of viral infections in childhood and ionizing 
radiation.(22) 
 
              Migration studies have shown that ovarian cancer rates approach those 
place of immigration rather than the place of emigration suggesting a significant 
environmental component to ovarian tumour risk. Genetic factors are an important 
ovarian cancer risk. Hereditary is responsible for approximately 10% cases due to 
the markedly increased risk conferred by the  BRCA 1 and  BRCA 2  tumour 
suppressor genes.(22,44) 
 
Many patients present with later stages in ovarian cancer. This is because, 
unlike cervical cancer, effective early detective screening programmes are not 
available for ovarian cancer. Nowadays, for screening purpose, ultrasound and 
serum CA 125 level are used. Regarding prevention of ovarian cancer, preventive 
measures that could be recommended on a population wide basis, such as diet 
modifications, cessation of smoking and prophylactic oophorectomy is often 
performed in patients at high risk of ovarian cancer.(22) 
 
 Cytokeratins are a family of water insoluble, intracellular fibrous proteins 
present in almost all epithelia. Keratin represents an excellent marker for epithelial 
differentiation regardless of whether the tumour is of endodermal, 
neuroectodermal, mesenchymal or of germ cell origin.(35,42) 
 
 It is a useful marker for primary ovarian tumours and various types of 
metastatic tumours in the ovaries. Immunohistochemistry is done to demonstrate 
various  patterns of cytokeratin  expression in epithelial and non epithelial 
tumours. 
 
 This study is undertaken in view of evaluating the actual incidence of 
ovarian neoplasms in a semi urban area like Thanjavur with particular attention to 
age, clinical features, histopathological and immunohistochemical features. In 
addition, the recent literatures, journals and research publications regarding 
ovarian tumors are also immensely reviewed.    
AIM OF THE STUDY 
 
1. To study the incidence of ovarian tumours in semi urban population, with 
clinical correlation. 
 
2. To study and compare the incidence of malignant ovarian tumours in relation 
to female genital tract malignancies. 
 
3. Application of histochemistry in selective cases. 
 
4. Application of immuno  histochemistry with study of cytokeratin expression in 
ovarian tumours. 
 
 
 
 
 
 
 
  
MATERIALS AND METHODS 
     
          132 cases presented  with ovarian neoplasms referred from Raja 
Mirasudhar Govt. Hospital (RMH), Thanjavur which is affiliated to Thanjavur 
Medical Collage (TMC) during 2006 to 2008 were included in this study. 
 
       We received ovariotomy specimen and also along with hysterectomy  
specimen.  A detailed history with particular attention to clinical symptoms and 
signs were recorded and thorough gross examination of the specimen were also 
done. Specimen were fixed in toto in buffered 10% neutral formalin and 
processed routinely. 
                  In cystic ovarian neoplasms, 4-5 bits were  taken from the wall along 
with papillary excrescences if present. In solid tumours, 3-4 bits were taken if the 
tumors were less than 5cm.  If more than 5 cm, one block per 1 cm of the tumour 
were taken across its greatest dimension, particularly if the appearance is 
variegated. 3-5 micro meter sections were cut and stained with haematoxylin and 
eosin (Appendix I ).  
 
             Reticulin or PAS were applied in doubtful cases(Appendix II,III). In 
all types of malignant  neoplasms,  cytokeratin   expression were also studied 
(Appendix IV ) . 
REVIEW OF LITERATURE 
 
ANATOMY  
 The ovaries are paired ovoid structures, homologous with the testis, but 
smaller. They have an average volume of 11cm3 in reproductively mature women. 
The ovaries are dull white in colour and consist of dense fibrous tissue in which 
ova are embedded. Before regular ovulation begins they have a smooth surface, 
but thereafter their surfaces are distorted by scarring that follows the degeneration 
of successive corpus luteum. The average size of the ovary is 3x2x1cm.(2)  
 
Diagram:1.Female reproductive tract. 
 
DEVELOPMENT  
 Ovary is developed from coelomic epithelium on the medial side of the 
mesonephrons. The surface epithelium covering the ovaries are modified 
peritoneum called germinal epithelium. Cords of cells proliferate from this 
germinal epithelium and grow into the underlying mesoderm. Primordial germ 
cells, that are formed in relation to the yolk sac, migrate to the region of the 
developing ovary, and give rise to oocytes.  
 The sex cords become broken up into small masses. The cells of each mass 
surround one primordial germ cells or oocyte to form a primordial follicle, 
interstitial gland cells differentiate from the mesenchyme of the gonad. As no 
tunica albuginea is formed, the germinal epithelium may contribute to the ovary 
even in postnatal life.(53)  
 
HISTOLOGY  
 The body of the ovary consists of spindle shaped cells, fine collagen fibres 
and ground substances that together constitute the ovarian stroma. Bundles of 
smooth muscle cells are also scattered throughout the stroma. In the peripheral 
zone of the stroma, known as the cortex, are numerous  follicles that contain 
female gametes in various stages of development.  
 The central zone of ovarian stroma, the medulla, is highly vascular and 
contain hilar cells, ovarian artery, collagen rich meshwork containing elastic fibres 
and few clusters of interstitial cells.(2)  
 There are three main categories of primary ovarian tumors. Epithelial 
tumours which derive from the surface epithelium of ovary, sex cord-stromal 
tumours, which arise from the ovarian stroma and from the sex cord derivation or 
both. Germ cell tumour which originate from germ cells(42,43,62).  
 Generally, one out of eight ovarian tumours in patients <45years of age is 
malignant, by contrast in older women, the proportion is about one of three. 
Teratoma is encountered at all ages. Primitive germ cell tumour is never seen >50 
years of age. The borderline surface epithelial tumour occur in women in their 30 
years of age.(43)  
 The granulosa cell and Sertoli Leydig cell tumours are typically unilateral. 
Tumours that metastasize to the ovary are always bilateral.(1,14,43)  
 Finally accurate diagnosis of ovarian tumour depends on a knowledge of 
the wide range of microscopic patterns they may exhibit and the cell types they 
may contain.(1,43) 
 
 
 
 
WORLD HEALTH ORGANIZATION – WHO 
HISTOLOGICAL CLASSIFICATION OF OVARIAN 
TUMOURS 
1. Surface epithelial tumours  
2. Sex cord – stromal tumours  
3. Germ cell tumours  
4. Gonadoblastoma  
5. Germ cell sex cord – stromal tumour of nongonadoblastoma type  
6. Tumours of Rete ovarii – adenoma, cystadenoma, adenocarcinoma 
7. Mesothelial tumours – adenomatoid tumour, mesothelioma 
8. Tumours of uncertain origin and miscellaneous tumours  
Small cell carcinoma  
Tumours of probable wolffian origin (FATWO) 
Hepatoid carcinoma 
Myxoma  
9. Gestational trophoblastic diseases  
10. Soft tissue tumours non specific to ovary  
11. Malignant lymphomas, leukemias, and plasmacytoma  
12. Unclassified tumours  
13. Secondary (metastatic) tumours  
14. Tumour like conditions  
SURFACE EPITHELIAL TUMOURS 
 Epithelial tumours are classified according to the predominant pattern of 
differentiation of the neoplastic cells. Each of the tumour type subdivided into 
benign, borderline and malignant categories.(7)  
 
HISTOLOGICAL TYPES OF SURFACE EPITHELIAL 
TUMOURS OF OVARY  
 
 
1. Serous tumours  
2. Mucinous tumours  
- Intestinal type  
- Endocervical type  
3. Endometrioid  
- Adenosarcoma  
- Mixed mesodermal tumour  
- Endometrioid stromal sarcoma  
4. Clear cell tumour  
5. Transitional cell tumours (including Brenner) 
6. Squamous cell tumours  
7. Mixed epithelial tumours  
8. Undifferentiated carcinoma  
 
 
SEROUS TUMOURS 
 Serous tumours comprise about 25% of all ovarian neoplasms. They are the 
most common epithelial tumours, accounting for 20% of benign, 40% of 
malignant primary ovarian tumours. Of all serous tumours, 50% are benign, 15% 
are borderline and 35% are invasive carcinoma.(7,8,21,25,44) 
 BENIGN SEROUS TUMOURS  
 Benign serous tumours include serous cystadenomas, serous 
cystadenofibroma, serous  adenofibromas  and  serous  surface  papillomas.  
GROSS  
 Cystic, usually have a smooth pale-yellow (or) gray white exterior with a 
prominent vascular pattern. It can be either unilocular (or) multilocular. When 
solid and cystic portions are both prominent the tumour is designated as a 
cystadenofibroma. 
 HISTOPATHOLOGY  
  Consists of a mixture of tall ciliated and non ciliated columnar cells with 
elongated oval nuclei interspersed with a variable number of peg shaped cells and 
clear cells. Psammoma bodies are small whorled calcified structure. They are 
numerous in some serous tumours, and may be found (30%) in cellular as well as 
acellular areas.(7,25,44)  
 
 
BORDERLINE SEROUS TUMOURS  
 Borderline are large, averaging about 8cm in maximum diameter. 30-40% 
are bilateral. Usually multicystic, numerous, coarse papillae form the cyst lining.  
MICROSCOPIC PICTURE  
 The most characteristic microscopic feature of a borderline serous tumour 
is a complex branching papillary pattern of growth. The papillae typically branch 
into progressively finer fronds, a pattern that is referred as hierarchial branching. 
The cells are stratified into several layers and they form tufts from which single 
cells or small clusters of cell detach into the cyst lumen. There is mild to moderate 
nuclear atypia and mitotic activity is less than in serous carcinoma. (7,22,25,44)  
 Recently, a group of borderline serous tumour with particularly prominent 
cellular proliferation has been recognized. These tumours are called 
micropapillary serous tumours.(7) 
 The only universally accepted criterion for differentiation between a 
borderline serous tumuor and serous carcinoma is the presence of stromal invasion 
in the latter. Microscopic stromal invasion is detected in 5-10% of borderline 
serous tumours. Multiple foci of microinvasion each less than 3mm in maximum 
dimension are typically present.(2,32,33)  
 
 
 
SEROUS CARCINOMA  
 Serous carcinoma is usually large, is often bilateral in about two thirds of 
all cases.(44) 
 
GROSS  
 Serous carcinomas range from predominantly cystic papillary tumours to 
entirely solid, soft or hard masses, often having papillary surfaces.(7,22,43,44)  
 
MICROSCOPIC FINDING  
 Microscopically, serous carcinoma is composed of low columnar cells. The 
degree of cytological atypia and mitotic activity is valuable. In high grade tumours 
which are the most common, the nuclei are markedly atypical and largely fill the 
cells. Bizzare and multinucleated cells are common, and very high mitotic rates 
are typical (often >50mf/hpf). The glands are often cleft like, rather than rounded, 
and they are lined by cuboidal or low columnar cells. The malignant cells diffusely 
infiltrate a fibrotic stroma and  foci  of  necrosis are commonly 
present.(7,14,22,31,44,62) 
 
MUCINOUS TUMOURS  
 Mucinous tumours account for 12-15% of all ovarian tumours. 
Approximately 75% of mucinous tumours are benign, 10% borderline, 15% 
carcinomatous.  
BENIGN MUCINOUS TUMOUR  
 Mucinous cystadenomas are cystic neoplasm, that have a smooth, blue-
white or gray external surface with numerous blood vessels. Most are >10cm in 
diameter. On cut surface reveals, thin walled mucin filled cysts ranging from a few 
mm to several cm in diameter. Benign are usually unilateral, only about 5% are 
bilateral.(6,7,22,44) 
MICROSCOPIC FINDING  
  Mucinous cystadenomas are lined by a layer of columnar mucinous cells, 
most of which resemble endocervical or  gastric mucinous cells. May have pale or 
clear cytoplasm and small bland basally situated oval nuclei.(7,22,44) 
 
BORDERLINE MUCINOUS TUMOURS OF INTESTINAL 
TYPE  
 
  Intestinal type neoplasms constitute by far the most common type of 
borderline mucinous tumour. Borderline tumours average 15-20cm in diameter 
and fewer than 10% are bilateral.  
 
GROSS  
 Borderline tumours tend to be multiloculated cystic neoplasms with 
variable amounts of fibrous stroma between the cysts.  
 
MICROSCOPIC PICTURE  
 These tumours are composed of proliferating mucinous epithelium. Bland 
areas in which the cysts are lined by endocervical or gastric type of cells are 
typically present, but there are some  areas in which cysts and glands are lined by 
intestinal type absorptive and goblet cells. The nuclei are basal, round to oval and 
mild to moderately atypical cells. The nuclei are typically stratified into two or 
three layers and scattered mitotic figures are present.(7,14,43,44) 
 
BORDERLINE [ENDOCERVICAL LIKE] MUCIONOUS 
TUMOURS    
 
                        Endocervical like mucinous borderline tumour have an architecture 
similar to that of serous borderline tumour, with both large, bulbous papillae and 
smaller papillae with prominent cellular budding. The papillae lined by slightly to 
moderately atypical epithelial cells. Mostly these cells have an abundant 
cytoplasmic mucin, but some may be mucin free and contain large amount of 
eosinophilic cytoplasm.  
 
MALIGNANT MUCINOUS TUMOUR 
  Ovarian mucinous adenocarcinomas differ from borderline tumours having 
evidence of ovarian stromal invasion.  
 
 
MACROSCOPY  
 Usually large, unilateral, smooth surfaced, multilocular, containing viscous 
mucoid material. Bilateral in approximately 5% of cases. Hemorrhagic, necrotic, 
solid or papillary areas are relatively frequent.(7,14) 
HISTOPATHOLOGY  
 There are complex papillary areas or back-to-back arrangement of glands 
lined by malignant appearing cells with little or no discernible intervening stroma.  
 To qualify as frankly invasive, the invasion  should be more than 5 mm. 
The invasion may be in the form of infiltrative glands, tubules, cords or cell nest 
with desmoplastic stroma.(14,25,43,44)  
ENDOMETRIOID TUMOURS 
 Endometrioid epithelial tumours account for 2 to 4% of all ovarian 
tumours. Coexistent with endometriosis in 10-20%. Benign, borderline, and 
malignant endometrioid epithelial tumours occur most commonly in women in the 
older reproductive and post menopausal age groups, with mean ages of 56,51 and 
56 years respectively.(44)  
BENIGN ENDOMETRIOID TUMOUR  
 The histological diagnosis of endometrioid adenomas and cystadenomas is 
based on the presence of well differentiated, benign appearing glands or cysts 
lined by endometrial type cells with or without squamous, differentiation.(14)  
 
BORDERLINE ENDOMETRIOID TUMOUR  
 Three pattern have been described. Islands of crowded endometrioid glands 
or cysts lined by cells displaying grade 1 to 3 cytological atypia proliferate in an 
adenofibromatous stroma. Stromal invasion is absent. Mitotic activity is low. 
Squamous metaplasia is common.The second is villoglandular papillary pattern. 
Third  is combination of villoglandular and adenofibromatous pattern.(14,25,47)  
MALIGNANT ENDOMETRIOID ADENOCARCINOMA       
 GROSS  
 The tumours, typically measuring 10-20cm in diameter, are solid, soft, 
friable or cystic with a fungating mass protruding into the lumen. They are 
bilateral in 28% of cases. 
HISTOPATHOLOGY  
 Ovarian endometrioid carcinomas closely resemble endometrioid 
carcinomas of the uterine corpus. The well differentiated form shows round, oval 
or tubular glands lined by stratified nonmucin containing epithelium. Squamous 
differentiation occurs in 30-50% of the cases, often in the form of 
morules.(4,14,22,44,47,56) 
CLEAR CELL TUMOURS 
 Benign clear cell tumours are rare and borderline forms account for less 
than1%. Clear cell carcinoma, however account for 6% of epithelial  cancers. 
Most clear cell carcinomas are diagnosed during 5th to 7th decade. Benign, 
borderline clear cell tumours are almost invariably unilateral.  
CLEAR CELL ADENOFIBROMA 
GROSS        
              Adenofibroma has a median diameter of 12cm and smooth external 
surface. The sectioned surface has a fine honey comb appearance with minute 
cysts embedded in a rubbery stroma.  
HISTOPATHOLOGY  
 It is characterized by tubular glands lined by one or two layers of 
epithelium that contains polygonal, hobnail cells. The cytoplasm may be clear, 
slightly granular or  eosinophilic. Nuclear atypia and mitotic activity are 
minimal.(52) 
BORDERLINE CLEAR CELL ADENOFIBROMATOUS 
TUMOUR  
HISTOPATHOLOGY  
 Adenofibromatous tumours in which the glands are lined by malignant 
epithelium are best designated as “borderline clear cell adenofibromas with 
intraepithelial carcinomas”. Nuclear atypia is more marked with coarse chromatin 
clumping prominent nucleoli and increased mitotic activity.  
CLEAR CELL ADENOCARCINOMA  
 The mean age of presentation is 57 years, tumours arise directly from the 
ovarian surface epithelium, from an inclusion cysts or from an endometriotic 
cyst.(14) 
 
 
GROSS  
 The mean diameter of clear cell adenocarcinoma is 15cm. Tumour may be 
solid. Cut surface reveals a thick walled unilocular cyst with multiple yellow 
fleshy nodules, protruding into the lumen or multiloculated cysts containing 
watery or mucinous fluid.(14)  
HISTOPATHOLOGY  
 Clear cell carcinoma is characterized by diffuse, tubulocystic, papillary and 
infrequently trabecular patterns. The most common clear cell types are clear, 
hobnail and flat. The clear cells are typically polyhedral, have distinct cell 
membranes contain abundant empty cytoplasm and eccentric nuclei. Hobnail cells, 
which are found in most of the tumours, are characterized by bulbous nuclei that 
protrude into the lumina of tubules and cysts, and line papillae. (43,50,52)   
TRANSITIONAL CELL TUMOURS 
 Transitional cell tumours, most of which are benign account form 1 to 2% 
of all ovarian tumours. Approximately 95% of Brenner tumours are diagnosed in 
women between the ages of 30 and 70 years. It usually coexists with mucinous 
cystadenoma.(8,22,44) 
BENIGN BRENNER TUMOUR 
 Typically small, <2cm in diameter 7-8% are bilateral. Gross examination 
reveals a sharply circumscribed, firm, nodular, smooth or slightly bosselated 
external surface. Cut surface shows white, but may be pale yellow colour. (44)  
MICROSCOPIC FINDING 
           Solid and cystic nests of epithelial cells resembling transitional epithelium, 
surrounded by abundant stromal component. The epithelial cells are sharply 
outlined. These are flattened, cuboidal or columnar epithelium. The nuclei are 
small with distinct nucleoli, conspicuous grooves  and clear cytoplasm.(25,44) 
BORDERLINE BRENNER TUMOUR 
          Only 3-5% of Brenner tumours are borderline.(14) 
GROSS  
 Borderline tumours are typically large with a median diameter of 16-20cm. 
May usually have a solid component.(7,14)  
MICROSCOPIC FINDING  
 Tumour exhibits proliferative activity and nuclear atypia. The tumour cells 
grow in nests and sheets and line papillary fronds that project into cyst lumens. 
Mitotic figures are usually present but not numerous.(7) 
MALIGNANT BRENNER TUMOUR AND TRANSITIONAL 
CELL CARCINOMA 
         Malignant Brenner tumour is almost always unilateral, size is 15cm in 
diameter. Most are partly cystic with solid, gray, yellow or tan areas often 
containing calcification.(7) 
 
 
MICROSCOPIC FINDING  
 Malignant Brenner tumour has a component of invasive carcinoma that 
resembles a transitional cell carcinoma of bladder(45). The tumour cells are 
polygonal and have eosinophilic cytoplasm. The nuclei are atypical and variably 
pleo-morphic. The degree of atypia and mitotic activity depend on the tumour 
grade. Benign or proliferating Brenner tumour must be identified  adjacent to these 
carcinomas.(7,11,14)  
SEX CORD - STROMAL TUMOURS 
     Neoplasms derived from the sex cords or ovarian mesenchyme comprise 
5-12% of all ovarian neoplasms. A few tumours in this group such as benign 
fibromas are common, but most are uncommon.(7,14)   
CLASSIFICATION OF SEX CORD - STROMAL TUMOURS 
OF THE OVARY  
1. Granulosa cell tumour  
Adult type  
Juvenile type  
2. Fibroma – thecoma group  
Fibroma  
Cellular fibroma  
Fibrosarcoma  
Thecoma  
Fibroma or thecoma with minor sex cord elements  
Sclerosing stromal tumour  
 
3. Sertoli –Leydig cell tumour  
Well differentiated  
Intermediate differentiation  
Poorly differentiated  
Retiform  
4. Sertoli cell tumour  
5. Sex cord tumour with annular tubules  
6. Steroid (lipid) cell tumor  
Leydig cell tumour  
Stromal luteoma  
steroid cell tumour   
7. Gynandroblastoma 
8. Soft tissue tumours not specific to the ovary  
9. Hematopoietic neoplasms (lymphoma, leukemia, plasmacytoma) 
 
GRANULOSA CELL TUMOUR 
            Granulosa cell tumours are the most common malignant sex cord-stromal 
tumours. May constitute 1-2% of all ovarian tumours. Adult type granulosa cell 
tumour occur in peri or post menopausal women.(7,22) The average patient age is 
about 52 years. It is a slow growing tumour.  
 
 
GROSS  
 The average diameter is about 10cm. Most are partly cystic and partly solid. 
The solid areas show tan, white, light yellow, or golden in colour. Intracystic 
hemorrhage is common.(43) 
MICROSCOPIC FINDING  
 They are small with uniform round or oval hyperchromatic nuclei. The 
nuclear chromatin is finely granular, longitudinal nuclear grooves or folds are 
often present. Mitotic activity is low.  
 Granulosa cell tumours grow in a variety of histological patterns. These are 
microfollicular pattern with Call Exner bodies, macrofollicular, trabecular, insular, 
solid or diffuse, gyriform or watered – silk pattern.  
JUVENILE GRANULOSA CELL TUMOUR    
GROSS 
 Less than 5% occurs in children, less than 15 years of age, average 12cm in 
diameter, most often solid with cystic areas.  
MICROSCOPIC FINDING  
 Macrofollicles and zones of diffuse solid growth. The tumour cells are 
large, have round dark nuclei with coarse chromatin. As a rule nuclear grooves are 
not present. Mitotic activity present (6/10hpf).(7,22,25,44) 
 
 
FIBROMA AND RELATED NEOPLASMS  
 Fibroma is a benign tumour that accounts for 1-5% of all ovarian tumours. 
Average age is around 50 years. 30% associated with ascites.  
GROSS  
 Usually small to medium, less than a centimeter to 10 cm in diameter, firm, 
solid with a tan or white cut surface.  
MICROSCOPIC FINDING 
  Composed of  fibroblastic cells that grow in whorls and interlacing 
fascicles. Mitotic figures are absent. Rarely small irregular nests or tubules of sex 
cord cells with small hyperchromatic nuclei and amphophilic cytoplasm are noted 
in fibroma or fibrothecoma. When there is mild to moderate nuclear atypia and 
there are 3 or fewer mitotic figure /10 hpf , classified as cellular fibromas. If the 
degree of nuclear atypia is moderate to marked, with 4 or more mitotic 
activity/10hpf, classified as  fibrosarcoma.(7,19)  
THECOMA 
         It comprises 7% of sex cord- stromal neoplasms. The average age is between 
50-55 years. 5% of patients have bilateral presentation.  
GROSS  
 It is firm or hard, average 7cm in diameter, cut surface reveals gray or tan 
with focal to extensive yellow areas .(19,62) 
 
MICROSCOPIC FINDING 
 Cells with uniform bland, oval and spindle shaped nuclei with abundant, 
pale, lipid-rich cytoplasm.(14) 
 SCLEROSING STROMAL TUMOURS 
          This tumour accounts for 2-6% of ovarian stromal tumours, >80% occurs in 
young women, presenting with menstrual abnormalities.  
GROSS  
  Typically unilateral. Cut surface reveals, solid, gray-white with occasional 
yellow foci and cystic areas.  
MICROSCOPIC FINDING  
 Pseudolobulation of the cellular areas separated by hypocellular areas of 
densely collagenous or edematous tissue with varying degrees of sclerosis 
admixed with both spindle and lipid containing round cells that may simulate 
Krukenberg tumour.  Lobular growth pattern with marked vascularity present.(25) 
SERTOLI- LEYDIG CELL TUMOUR 
 Sertoli-Leydig cell tumours are rare and comprises less than 1% of ovarian 
tumour. Most occurs in young women. More than 50% are hormonally active, 
patients have menstrual disorders or virilization.(7) 
 
 
 
MICROSCOPIC PATTERNS  
1. Well differentiated, Meyer`s type I (11%)54 
Composed of tubules lined by Sertoli like cells, separated by variable 
number of Leydig cells.  
2. Intermediate, Meyer`s type II (54%) 
Composed of cords, sheets and aggregates of Sertoli like cells, separated by 
spindle stromal cells and recognisible Leydig cells.  
3. Poorly differentiated (sarcomatoid, undifferentiated Meyer’s type III) 
Composed of masses of spindle shaped cells arranged in a sarcomatoid pattern.  
 
SERTOLI CELL TUMOUR 
          Pure Sertoli cell tumours are rare. They are most common in women of 
reproductive age. Sertoli cell tumours are unilateral and average 5-7cm diameter. 
Usually solid tumours, cut surface is tan or yellow.  
 
MICROSCOPIC FINDING 
  Composed of Sertoli cells that line tubules or trabeculae or grow in nests or 
solid sheets. Cells are columnar or polygonal and have small, round to oval nuclei 
and granular or eosinophilic cytoplasm. Rarely Sertoli cell tumours are composed 
of lipid-rich and oxyphilic Sertoli cells. Nuclear atypia is minimal.(7,14) 
 
GYNANDROBLASTOMA 
          Gynandroblastoma is a rare tumour, containing both Sertoli cell or Sertoli- 
Leydig cell and granulosa cell differentiation. Usually, unilateral with size ranging 
from 1cm to 18cm. Microscopically, tubules and trabeculae similar to those in 
well differentiated Sertoli or Sertoli-Leydig cell tumours mixed with nests and 
sheets of granulosa cells.  
GERM CELL TUMOURS 
  Except benign cystic teratoma (dermoid cyst),germ cell tumours of the 
ovary are uncommon. Malignant germ cell tumours almost always occur in 
children and women less than 30 years of age.  
 
CLASSIFICATION OF GERM CELL TUMOURS OF 
OVARY  
• Dysgerminoma   
• Yolk sac tumour (endodermal sinus tumour) 
• Embryonal carcinoma  
• Polyembryoma  
• Choriocarcinoma  
• Teratoma  
Mature teratoma  
Solid, cystic, immature teratoma 
Neuro ectodermal tumour  
 
• Malignant tumour arising in a mature teratoma  
• Monodermal teratoma  
Struma ovarii  
Carcinoid tumour  
• Mixed germ cell tumour  
• Gonadoblastoma  
• Unclassified germ cell tumour  
DYSGERMINOMA 
       Dysgerminoma is the most common malignant germ cell tumour of the ovary 
and it accounts for 1-2% of malignant ovarian tumours.(43) 
 The average age is 22 years. Dysgerminoma is the most common malignant 
tumour in patients with gonodal dysgenesis. It is usually unilateral. 
GROSS  
  Dysgerminoma is a firm, solid tumour with smooth, nodular external 
surface. Cut surface is homogenous, fleshy and is tan or white.  
MICROSCOPIC FINDING  
 Well defined nests separated by fibrous strands infiltrated by lymphocytes. 
The tumour cells are large polygonal cells with vesicular nuclei, abundant clear 
cytoplasm, and prominent nucleoli.(7)  
 
 
YOLK SAC TUMOUR 
            Yolk sac tumours are most common in the second and third decades. The 
median age is between 16 and 19 years. Almost all the patients have an elevated 
serum levels of alpha feto protein.  
  
GROSS  
 The median diameter of tumour is 15cm. External surface is smooth and  
glistening. 25% have capsular tears. Cut surface reveals solid with cystic, friable, 
yellow to gray tissue, with extensive areas of hemorrhage and necrosis are 
common.(44)   
 MICROSCOPIC FINDING  
 Yolk sac tumours exhibit a wide variety of microscopic patterns, but most 
tumours have atleast focally, a reticular pattern. It is characterized by a loose 
meshwork of communicating spaces lined by primitive tumour cells. With 
cytoplasm, that is clear, containing glycogen, occasionally lipid. Nuclei are large, 
hyperchromatic, irregular with prominent nucleoli. Mitotic figures are numerous.                           
The presence of Schiller-Duval bodies is a characteristic feature of yolk sac 
tumour.(44) Also variable sized brightly eosinophilic PAS positive intracellular 
hyaline bodies are present in most of  the yolk sac tumour.    
 
EMBRYONAL CARCINOMA 
        The median age is 15, have precocious puberty with increased alpha feto 
protein. 
GROSS  
       The external surface is smooth, glistening. Cut surface is solid with variegated 
appearance.  
MICROSCOPIC FEATURE  
  Primitive cells are arranged in solid sheets, and nests, occasionally forming 
papillae and abortive glandular elements.(25) 
CHORIOCARCINOMA 
       Extremely rare tumour. Most often seen in the ovary as a component of a 
mixed germ cell tumour.(7) 
TERATOMA 
          It comprises  26% - 44% of all ovarian tumours. Most teratomas contain 
tissues from the various germ layers and consequently have a varied morphology.  
In some teratomas one germ cell derivative will predominate which is called as 
monodermal teratomas.(7) 
 
 
 
MATURE (BENIGN) TERATOMA 
       The most common tumour in this category is a benign cystic teratoma or 
dermoid cyst. It is detected at any age, but 85% are between 20 and 50 yrs and 
10% are bilateral.(17)    
GROSS  
 Predominantly solid with small cystic areas, composed of all three germ 
cell layers.(25) 
MICROSCOPIC FEATURE  
 Tumour exhibit 100% ectodermal derivatives, 93% mesodermal and 71% 
of endodermal structures.(25) 
IMMATURE TERATOMA 
           Is a malignant teratoma in which the malignant elements have an 
embryonal appearance. Occurs predominantly in children and young adults. 
Histological grading is done by assessing the amount of immature tissue and  
neuroepithelium.  
MIXED GERM CELL TUMOUR 
           This tumour contains varied mixture of malignant germ cell elements. It 
comprises 5-20% of all malignant germ cell tumours. The average age is 18 years.  
GROSS  
 Usually larger size, 15cm in diameter. Apperance depends upon the 
elements that are present.  
 
 MICROSCOPIC FINDING 
  Mixed germ cell tumour contains atleast two malignant elements, 
commonly dysgerminoma and yolk sac tumour. Dysgerminoma is the most 
frequent element along with embryonal carcinoma, choriocarinoma, and 
polyembryoma. Also other combinations of both choriocarcinoma and 
polyembryoma may occur .(7,43,44) 
GONADOBLASTOMA 
            A rare tumour found almost exclusively in abnormal gonads. It consists of 
a mixture of germ cells and sex cord cells.  
 Gonadoblastoma is benign unless a germinoma or some other type of 
malignant germ cell tumour arises from it.  
GROSS  
 Small 2-3cm, 40% bilateral, cut surface shows tan or white and foci of 
calcification frequently seen.(7,44) 
MICROSCOPIC FINDING  
 Contains nests of germ cells and sex cord cells surrounded by fibrous 
stroma. The stroma between the nests of tumour cells often contains luteinised 
cells as well as microcalcifications in post pubertal patients. 
 
 
 
METASTATIC TUMOURS 
         Gastrointestinal, breast, and uterine carcinomas frequently metastasize to the 
ovaries. Metastatic cancer comprises 10% of all ovarian cancers.(7) 
 The characteristic features of metastatic disease are bilateral presentation 
with smaller size than primary ovarian tumours, nodular growth pattern, surface 
involvement, infiltrative growth, prior or synchronous extraovarian primary 
neoplasm of similar histologic appearance that is more microinvasive and involves 
other than just the ovary.(22,23,44)  
 The features characteristic of primary ovarian tumours are large unilateral, 
multicystic tumour without nodularity, surface involvement, capsular invasion, 
with confluent glandular expansile pattern, or even an atypical proliferative, 
[borderline] type growth pattern, apparently isolated involvement of the 
ovary.(23,25)  
KRUNKENBERG TUMOUR 
        Is the form of metastatic cancer in which a signet ring cell carcinoma grows 
in abundant hypercellular stroma.(7) The Krukenberg tumour is almost always 
secondary to a gastric carcinoma.(14) 
 The features supportive of the diagnosis of a metastasis include bilaterality, 
histological surface involvement by epithelial cells, irregular infiltrative growth 
with desmoplasia, single cell invasion, signet-ring cells, vascular invasion, 
coexistence of benign-appearing mucinous areas, with foci of mitotic figures, 
nuclear hyperchromasia and histological surface mucin.(1,14) 
CYTOKERATIN 
          Keratins are intermediate filament proteins that contribute to the cytoplasm 
of epithelial cells. As they are present in all epithelial cells, immunostains for 
cytokerain are useful as a screening test to identify a neoplasm as being of 
epithelial type.  
 Human cytokeratin have been classified according to their molecular 
weight and isoelectric Ph in the catalog published by Mollet al. 20 epithelial 
cytokeratin polypeptides have been identified. Some of these have specific tissue 
distribution that can be exploited for the differential diagnosis of tumour. For 
screening purposes, a wide spectrum of antibodies that recognise many different 
CKs are most valuable, such as cocktail of AE1/AE3 and CAM5.2. (22,42,51)  
CK7  
CK 7 is a type II basic low molecular weight cytokeratin found in simple 
epithelium in a variety of organs including epithelial cells in female genital tract.  
 Epithelial tumours of ovary and fallopian tube all exhibit cytoplasmic and  
membrane staining for cytokeratin 7.   
 This characteristic staining pattern of female genital tract tumours can be 
used, usually in combination with staining for other keratin, such as CK 20, to 
differentiate primary female genital tract adenocarcinoma from adenocarcinoma 
arising in other organs.   
 A panel of immunostains needs to be evaluated because some primary 
ovarian neoplasms fail to stain for CK 7 and a proportion of metastatic carcinomas 
in the ovary are CK positive.  
CK 20 
  CK 20 is a type I acidic, low molecular weight cytokeratin, that was 
initially described in 1992. It is found in normal tissues of stomach, intestine, 
urothelium and in Merkel cells.  
 It is found in most adenocarcinomas of large and small intestine, in 
mucinous tumours of the ovary, and in Merkel cell carcinomas, and it is frequently 
present in urothelial carcinomas and in adenocarcinoma of stomach, pancreas and 
bile duct.  
 It is a useful marker for primary mucinous tumours and for various types of 
metastatic tumours that are found in the ovaries. Most primary non-mucinous 
epithelial tumours are cytokerain negative.(42)  
 
 
KEY DIAGNOSTIC POINTS : OVARIAN EPITHELIAL 
TUMOURS  
 
• All common primary epithelial tumours of ovary express cytokeratin 7. 
• If an epithelial tumours is CK 7 negative, consider a metastatic or one of 
the rare types of primary epithelial tumours.  
• Most primary ovarian tumours are CK 20 negative, except the intestinal 
type of mucinous ovaries tumour are positive with CK 20 and CK 7 . 
• The soft epithelial keratin intermediate filaments comprise approximately 
20 different keratin polypeptides of the approximate 30 keratin 
polypeptides.  
• The polypeptides numbered 1 through 20, comprise type II (basic) keratins 
and the type I (acidic) keratin.(42,44,51) 
 
 RETICULIN STAIN  
 The diffuse pattern of granulosa cell tumours may be confused with a 
benign thecoma, particularly when there is luteinsation. A reticulin stain is helpful, 
since granulosa cells typically grow in sheets, or aggregates bound by reticulin 
fibres, whereas thecomas contain an abundance of intercellular fibrils surrounding 
individual cells. The distinction is important since granulosa cell tumour have an 
aggressive potential, where as thecomas are with rare exceptions benign.(14) 
 
PAS  REACTION 
 Malaprade introduced periodic acid. Mcmanus first applied PAS Reaction. 
The basic principle is periodic acid oxidize compounds having free hydroxyl 
groups that are next to each other i.e., 1,2 glycol, bond between neighbouring 
carbon atoms is brokened and a dialdehyde structure is produced. This dialdehyde 
reacts strongly with Schiff reagent.(18) 
 PAS positive substances are many but it is positive with mucins of 
intestine, peptic gland, uterine cervical glands, salivary glands, bronchial glands, 
ovarian follicular cyst, prostatic gland secretion – corpora amylacea and renal 
hyaline casts. The positive substances are magenta in colour.(8,43) 
 In most of the Krukenberg tumours, PAS staining with or without diastase  
and alcian blue staining will be more extensively positive. PAS reaction will also 
be  positive in ovarian origin of mucinous tumours.    
   
 
  
 
 
 
 
 
 
 
 
 
OBSERVATION AND RESULTS 
This prospective study covered a total number of 132 ovarian neoplasms 
during the period of Jun 2006 to May 2008. 
 
I : INCIDENCE : 
The following table shows the total number of ovarian neoplasm among 
female neoplasms . 
 
Table 1 :  
SL.NO PERIOD 
TOTAL NO. OF 
FEMALE 
NEOPLASMS 
TOTAL NO. OF 
OVARIAN 
NEOPLASMS 
% 
1 Jun 06–Dec 06 451 33 7.3 
2 Jan 07–May 07 329 39 11.8 
3 Jun 07–Dec 07 546 28 5.0 
4 Jan 08–May 08 290 32 11.0 
 Total 1616 132 8.17 
 
  
The average incidence of ovarian neoplasms (including benign and malignant) 
among females are 8.17 %.                                        
 
II . AGE :  
In this study ovarian neoplasms were in the age group ranging from 10 to 
79 years. When the patients were divided into 7 groups according to their age, 
(i.e., 10 to 19 yrs, 20 to 29 yrs, 30 to 39 yrs, 40 to 49 yrs, 50 to 59 yrs, 60 to 69 
years and 70 to 79 yrs), there was a high incidence of ovarian neoplasms in the age 
group of 40 – 49 yrs followed by 20 – 29 yrs and the low incidence is seen in more 
than 70 yrs of age. 
      The distribution of cases according to their age is given in the following table 
2. 
 
Table 2 :   
SL.NO AGE IN YEARS TOTAL NO. OF CASES % 
1 10 – 19 13 9.8 
2 20 – 29 31 23.5 
3 30 -  39 24 18.2 
4 40 – 49 39 29.5 
5 50 – 59 20 15.2 
6 60 – 69 4 3.0 
7 70 – 79 1 0.85 
 Total 132  
  
 
Likewise the neoplasms were also divided into benign, borderline and 
malignant categories as given in the following table. 
Table 3 : 
SL.NO AGE IN YRS BENIGN BORDERLINE MALIGNANT 
1 10 – 19 10 - 3 
2 20 – 29 22 4 5 
3 30 -  39 14 6 4 
4 40 – 49 20 5 14 
5 50 – 59 07   11 
6 60 – 69 03 - 1 
7 70 – 79 - - 1 
 Total 76           (57.5%) 
17           
  (13%) 
39             
(29.5%) 
 
 The above table shows the highest incidence of benign neoplasm in 20 – 29 
yrs (22 out of 76 cases, 29%), borderline neoplasm in 30 – 39 yrs (6 out of 17 
cases, 35.2%) and malignant neoplasm in 40 – 49 yrs (14 out of 39 cases, 36%). 
 
The table also shows that after 50 years, most of the ovarian masses are 
malignant, and malignant neoplasms are also encountered below 20 years of age(3 
cases, 7.7%). 
  
 
 
Diagram 2 : Frequency distribution of ovarian neoplasms,  among different 
age groups 
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IV CLINICAL EVALUATION 
All the cases were evaluated clinically at the time of admission along with 
basic investigations as in the following table 4. 
Table  4 : Clinical presentation 
SL.NO CLINICAL FEATURES NO.OF CASES % 
1 Mass abdomen 86 65.15 
2 Pain abdomen 20 15.15 
3 Acute abdomen 2 1.52 
4 Ascites 8 7.58 
5 Bleeding   Per  vaginum 5 3.79 
6 Associated with pregnancy 6 4.55 
7 Asymptomatic 5 3.79 
  
 
Abdominal mass is the most common clinical presentation (86 cases, 
65.15%)   followed by pain (20 cases, 15.15 %). Few cases presented as acute 
abdomen necessiating emergency laparotomy. Abnormal vaginal bleeding in the 
post menopausal period is also noticed in 5 cases. 6 cases were found to be 
associated with pregnancy which was removed during LSCS.  5 cases were 
asymptomatic and detected during routine abdominal ultrasonography done for 
other causes.  
 
 
 
Diagram 3 : Pie chart depicting the percentage of signs and symptoms among 
ovarian tumour patients 
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V.LATERALITY : 
Likewise tumours were also categorised as with unilateral / bilateral 
ovarian involvement as in the given table. 
Table 5 : 
SL.NO TUMOURS UNILATERAL % BILATERAL % 
Serous 
Benign  32  1  
Borderline 8  2  
Malignant  9  6  
1 
Total 49 37.1 9 6.8
Mucinous 
Benign 26  1  
Borderline 6  1  
Malignant  4  2  
2 
Total 36 27.3 4 3.0
3 Endometrioid carcinoma 1 0.8 1 0.8
4 Transitional 1 0.8 0  
5 Sexcord- stromal tumor 6 4.5 0  
6 Germ cell tumor  18 13.6 1 0.8
7 Metastatic -  5 3.8
8 Gonadoblastoma (Fig-17&18) 1 0.8 0  
 Grand Total 112  20  
 
Most of the Serous tumours (Fig1&2) were unilateral at the time of 
presentation (49 cases, 37.1%) , as in mucinous tumours (36 cases, 27.3 %) and in 
germ cell tumors(Fig3), (18 cases, 13.6%).Bilaterality in serous and mucinous 
tumours as a whole was less than  9.8%. (13 cases). 
 All cases of metastatic ovarian tumours were bilateral at the time of 
presentation (5 cases, 3.8 %).  
VI.GROSS/HISTOMORPHOLOGY OF OVARIAN NEOPLASMS 
 The ovarian neoplasms were divided into following types as in table 6 
according to Histomorphology. 
 
Table 6 :   
 
SL.No GROSS MORPHOLOGY NUMBER OF CASES 
1 Pure Solid 10 
2 Pure Cystic 83 
3 Mixed Solid & Cystic 9 
4 Cystic with Papillary excrescences 21 
5 Solid with variegated appearance 05 
6 Solid & Cystic with areas of calcification 04 
 Total 132 
 
 
 
 
VII. DISTRIBUTION OF OVARIAN NEOPLASMS ACCORDING TO 
HISTOLOGICAL CLASSIFICATION. 
Table 7 : 
SL.No CLASSIFICATION No. OF CASES 
TOTAL 
CASES % 
Surface epithelial Tumour 
Benign 59   
Borderline 17 101 76.5 
1 
Malignant 25   
Germ-cell Tumour 
Benign 14   
2 
Malignant 4 18 13.6 
Sexcord-stromal 
Benign 1   
3 
Malignant 6 7 5.3 
4 
Metastatic 5 5 3.7 
5 
Gonadoblastoma 1 1 0.76 
 Total 132 132  
 
 
Out of 132 neoplasms surface epithelial tumours predominate with 101 cases 
(76.5 %), followed by germ cell tumours 18 cases (13.6 %) and sexcord- stromal 
tumours 7 cases (5.3 %). 
 
 
Diagram 4 : Pie chart depicting the percentage of ovarian tumours according 
to histologic classification 
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VIII : SUB-CLASSIFICATION OF SURFACE EPITHELIAL 
TUMOURS 
Surface epithelial tumours were also classified according to WHO 
classification as in the following table 8. 
Table 8 : Sub-classification of surface epithelial tumours. 
SURFACE EPITHELIAL 
METASTATIC OTHERS
GERM CELL TUMOUR
SEX CORD-STROMAL TUMOUR
SL.No CLASSIFICATION No. OF CASES % AVERAGE % 
Serous 
Benign 29 54  
Borderline 7 13  
Malignant 17 22  
1 
Total 53  52.0 
Mucinous 
Benign 27 63  
Boderline 10 23  
Malignant 6 14  
2 
Total 43  43.0 
Endometrioid 
Malignant 2 50  
3 
Total 2  4.0 
4 Clear cell tumour - - - 
Transitional 5 
Benign Brenner 1  1.0 
 Grand Total 101   
 
 Serous tumours (Fig-7) predominate 53 cases, 52.4%) followed by 
mucinous tumours(Fig-8) (43 cases, 42.5%), 2 cases of endometrioid tumour and 
one case of transitional cell tumour were also observed.  
 
IX. Sexcord-stromal Tumours 
Likewise Sexcord-stromal tumours and germ cell tumours were also 
classified according to the following table 9 - A & B. 
Table 9-A : Sexcord-stromal Tumours 
SL.No CLASSIFICATION NO OF CASES % 
1 Granulosa cell tumour   
 Adult 4 71.4 
 Juvenile 1  
2 Fibrothecoma 1 14.3 
3 Fibroma with sarcomatous change 1 14.3 
4 Others -  
 Total 7  
 
 5 cases of granulosa cell tumours(Fig-5&11) (71.4 %) and one case of 
fibrothecoma(Fig-12) and one case of fibroma with sarcomatous changes were  
observed. 
Diagram 5 :Bar chart ; percentage of sexcord – stromal tumour sub types 
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B:  Germ Cell Tumours.            
Table-9-B 
SL.No CLASSIFICATION NO. OF CASES. % 
1 Teratoma   
 Benign 14 77.7 
 Malignant -  
2 Dysgerminoma(Fig-13) 1 5.5 
3 Mixed Germ cell tumour 3 16.6 
4 Others -  
 Total 18  
  
In Germ cell tumours, most of the tumours were benign mature cystic 
teratomas (14 cases, 77.7 %) followed by mixed germ cell tumours(Fig-14&15)        
( 3 cases, 16.6%). 
Diagram 6 : Pie chart depicting the incidence of germ cell tumours 
 
 
 
 
 
 
 
 
 
 
X. HISTOCHEMISTRY  - PAS 
 In few doubtful cases of Krukenberg (Fig-6,16&21) and mucinous 
cystadenocarcinoma,(Fig -22) histochemical stain (PAS) was applied and results 
are given in the following table10. 
Table 10 : 
Dysgerminoma
17%
Mixed Germ Cell
6%
Teratoma - 
Benign
77%
 
SL.No PATH No HPE  DIAGNOSIS PAS REACTION PATTERN
1 G 692 / 66 Krukenberg tumour Positive Focal 
2 G 1000/07 Mucinous cystadenocarcinoma Positive Diffuse 
3 G 1279/07 Mucinous cystadenocarcinoma Positive Diffuse 
4 G 1334/07 Mucinous cystaenocarcinoma Positive Focal 
5 G 333/07 Krukenberg tumour Positive Focal 
 
XI. HISTOCHEMISTRY  - RETICULIN STAIN 
Also in solid variants of sexcord-stromal tumours and fibrothecoma, 
reticulin was applied and the results are given in the following table 11. 
Table 11 : 
SL.No HPE. No HPE DIAGNOSIS 
RETICULIN 
REACTION PATTERN 
1 G 516/06 Fibro Thecoma  (Fig-22) Positive 
Investment of 
Individual Cells. 
2 G1625/06 GranuIosa cell tumour (Fig-23) Positive 
Surrounding 
nests 
3 G 91/06 Granulosa cell tumour Positive 
Surrounding 
nests 
4 G1415/07 Granulosa cell tumour Positive 
Surrounding 
nests 
 
XII. IMMUNOHISTOCHEMISTRY 
The value of immuno histochemical marker, pancytokeratin was also 
evaluated in all malignant ovarian  neoplasms as given in the table 12 and the 
results are expressed as positive (focal,  diffuse)  and  negative. ( Fig -24 to Fig -
30) 
Table 12 : 
S.NO HPE NO 
TUMOUR 
DIAGNOSIS MARKER PATTERN 
1 G 973 A / 06 
High grade papillary 
serous cystadeno 
carcinoma 
Cytokeratin Positive-Diffuse 
2 G 1334/B/07 B/L mucinous cystadenocarcinoma Cytokeratin Positive-Diffuse 
3 G 1439/B/07 B/L Krukenberg tumour Cytokeratin Positive-Diffuse 
4 G 960 B / 07 Mixed germ cell - choriocarcinoma Cytokeratin Positive-Focal 
5 G 960 / 07 
Mixed germ cell – 
Embryonal 
cell component 
Cytokeratin Positive-Focal 
6 G 333 / 07 Krukenberg tumour Cytokeratin Positive-Diffuse 
7 G 239 / 06 
Poorly differentiated 
serous cystadeno 
carcinoma 
Cytokeratin Focal-positive 
8 G 221 / 08 
Gonadoblastoma 
dysgerminoma 
component 
Cytokeratin Focal-Positive 
9 G 221 / 08 Granulosa cell component Cytokeratin Focal-Positive 
10 G 242 / 08 Fibroma with sarcomatoid change Cytokeratin Negative 
 
DISCUSSION 
Ovarian cancer has emerged as one of the most common malignancy  
affecting women. The absolute number of new cancer patients in India is 
increasing rapidly due to an increase in the size of the population as well as an 
increase in the proportion of elderly persons due to improved life expectancy.(30) 
There is a wide variation in incidence between countries and also within any 
country for which several causes are cited. The increased diagnosis is partly due to 
more widespread screening programmes, improved certification and an alteration 
in registration procedures in certain countries.  
 
Most ovarian cancers are environmental in origin. Hence increase in 
exposure to risk factors also plays a pivot role in incidence of ovarian cancer. 
Nandagudi Srinivasa Moorthy et al has observed that some of the very widespread 
changes in the incidence of ovarian cancer may be accounted for by the trends, in 
aspects of reproductive behavior such as progressively smaller family size, 
nulliparous women and proportion of unmarried women. Parity and combined oral 
contraceptive use have been consistently documented as the protective factors.(36) 
 
In a review on epidemiology of ovarian cancer, cosmetic talc use and some 
aspect of diet (i.e. saturated fats, refined carbohydrates) may be associated with 
the increased risk of ovarian cancer .(36) 
Women with a family history of ovarian and breast cancer in first degree 
relatives have also been reported to be at increased risk. (36)  No such association 
has been found in our study. Nandakumar et al has observed that tubectomy as a 
method of family planning appeared to reduce the risk of development of ovarian 
cancer, but the follow up data is unavailable. 
A  COMPARATIVE ANALYSIS 
 In our study we  observed that the ovarian malignancy accounted for 3.39% 
of total female malignancies.  
 The following table illustrates the incidence of malignant ovarian 
neoplasms observed in our study. 
Table 13 : 
SL.NO PERIOD 
NO OF 
MALIGNANCIES 
IN FEMALES 
NO. OF 
MALIGNANT 
OVARIAN 
NEOPLASMS 
% 
1 Jun 06 – Dec 06 372 17 4.6 
2 Jan 07 – May 07 239 10 4.1 
3 Jun 07 – Dec 07 330 7 2.2 
4 Jan 08 – May 08 211 5 2.3 
 Total 1152 39 3.39 
 
 
The incidence of ovarian carcinoma by various studies as per the literature and 
journals is given below : 
PLACE OF STUDY                       
INCIDENCE 
1. Indian Cancer Society, Mumbai.                         7.27% 
2. Dr.B.R.Ambedkar Institute Rotary Cancer Hospital,                       7.19% 
 All India Institute of Medical Sciences, New Delhi. 
3. Gandhi Medical College, Bhopal.                         6.53% 
4. The Gujarat Cancer and Research                         6.06% 
    Institute, Ahamadabad. 
5. Kidwai Memorial Institute of Oncology,                         5.19% 
     Bangalore 
6. Cancer Institute, WIA, Adyar Chennai.                         5.11% 
7. Nargis Dutt Memorial Cancer Hospital, Barshi.                        3.37% 
8. PRESENT STUDY                            3.39% 
      
Of all these studies, Mumbai holds the top ranking with the incidence rate 
of 7.27%, and the least is Barshi with the incidence rate of 3.37%.  These 
observations suggest that the possible environmental and life style factors have an 
influence on the incidence rate.  India is rapidly stepping towards industrialization.  
Hence in urban areas like Mumbai changes in life style factors such as increase in 
age of marriage, delay in age at first birth, reduction in parity and improved socio-
economic conditions might have contributed to the increase in incidence in 
contrast with the rural area like Barshi with the lower incidence.  In our study 
conducted in a semi urban area , the incidence of ovarian malignancy is in midway 
between rural area like Barsi and urban area like Chennai. 
 
Diagram 7 : Bar chart depicting comparative analysis of incidence in ovarian cancer 
of our study with various  other studies. 
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 1. Indian Cancer Society, Mumbai. 2. Dr.B.R.Ambedkar Institute RotaryCancer Hospital, All India 
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We also observed that incidence of ovarian malignant neoplasm among the 
female genital tract malignancies,as per the following table 14, is 7.17%, which is 
the second common female genital tract neoplasm. 
Table 14 :                        
SL.No SITE NO OF FEMALE GENITAL TRACT MALIGNANCY % 
1 Cervix 488 89 
2 Ovary 39 7.17
3 Endometrium 12 2.2 
4 Vulva 4 0.7 
5 Vagina 3 0.5 
6 Fallopian tube - - 
 Total 544  
                                     
Diagram 8: Bar chart depicting percentage of various female genital tract 
malignancies. 
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The age specific incidence of ovarian neoplasms ranges from 20 -70 years 
as per the studies, journals and literature and also show increased incidence at 
specific age groups for each category of benign, borderline and malignant 
tumours.  The incidence of benign neoplasms peaks through 2nd to 4th decade in 
accordance with the literatures. As per the literature and studies conducted by 
various authors, borderline forms are detected after the age of 40 years and 30-
40% of them after the age of 65 years. (44)  In contrast, in our study borderline 
tumours stand in peak at the 3rd decade. 
Like, the age specific incidence of malignant ovarian neoplasms reaches 
peak in the 4th to 5th decade and in 6th decade it constitutes less than 3% in contrast 
to the studies of Nandagudi Srinivasa Murthy et al in which the ovarian cancers 
peak in the fifth and sixth decade of life.  Serous carcinoma is exceedingly rare in 
Ist two decades according to the literature.(36) In contrast, in our study 7.6% of 
cases were noted in first two decades. 
 Seventy percent of women with the ovarian cancers are diagnosed with 
stage III or IV disease with 5 years survival of less then 15%. Late diagnosis is 
thought to be at least in part due to vague non specific symptoms which can often 
go unrecognized for a period of time.(10,48)  So, efforts to improve disease outcome 
by detecting the disease at an early stage have focused on screening  asymptomatic 
women. 
 
According to the studies of BD Rufford et al 87% had abdominal 
symptoms, 41% had gastrointestinal,29% had constitutional symptoms and  only 
2% presented with mass abdomen(48).  In accordance in our study also 90% of the 
cases presented with abdominal symptoms. None of them had gastrointestinal or 
constitutional symptoms. 
Due to non specific symptoms there was a significant delay in the referral 
for an ultrasound scan or CA 125 blood test. 67 percent of the cases presented with 
mass abdomen at a higher stage. 
In future trials the delay in diagnosis, can be overcome with the use of 
patients information leaflets or symptoms questionnaires when women attend out 
patient department. Hence educating women about symptoms will result in earlier 
intervention by targeted screening and we can achieve a stage shift in survival 
improvement and mortality reduction. 
Bilaterality is a common feature of tumour that has metastasized to the 
ovary and is an important diagnostic clue.(43) Certain primary ovarian neoplasms 
also exhibit the feature of bilaterality.  
 
As per the literature bilateral presentation of serous cystadenoma is 7-20%, 
in contrast in our study it contributes only to 0.5% where as in borderline and 
malignant serous neoplasms it correlates well with the literature giving the 
percentage of 22.2% and 40% respectively.(44) 
 
Like wise the incidence of bilateral presentation of mucinous cystadenoma 
and mucinous cystadenocarcinoma are 3.7% and 33.3% respectively in correlation 
with the literature, where as it is in contrast with the bilateral borderline mucinous 
tumour, it is 14.2% only.  Endometrioid carcinoma shows bilateral presentation in 
only one case of all the tumours. Metastatic tumours predominant with bilateral 
presentation of 100%. 
In our study surface epithelial tumour observed in 101 cases (76.5%) stands 
as the most common ovarian neoplasms followed by germ cell tumour with 18 
cases (13.6%) and sexcord – stromal 7 cases (5.3%), metastatic tumours contribute 
5 cases (3.7%). Rare cases such as gonadoblastoma was also observed in this 
study. 
        Of the surface epithelial tumours serous tumours contribute to 52.4% of 
which 54% are benign serous cystadenoma, 13% are borderline and 17% are 
carcinomas in accordance with literature. (26,27,49) 
      Of the mucinous tumours, 63% are benign and 14% are malignant in 
accordance with the literature but, the borderline mucinous tumours contribute to 
23% in contrast with the literature giving the frequency of 10%. 
Low malignant potential (LMP) or borderline neoplasms derive from the so 
called surface epithelium of the human ovary, a modified mesothelium in 
continuity with the adjacent extra-ovarian peritoneum. These neoplasms represent 
an important category of ovarian common epithelial tumors usually associated 
with an excellent prognosis but rarely with a more aggressive and unpredictable 
behavior characterized by intraperitoneal seeding and frank malignant 
transformation. 
The diagnostic challenge associated with LMP ovarian neoplasms begins at 
the exploratory laparotomy.  At this time the gynaecologic surgeon must assess 
several issues including (1) Ovarian or Para ovarian location and extent of 
problems.  (2) Presence of adhesions between ovary and surrounding structures. 
(3) Indication for staging omentectomy, sub diaphragmatic smears and peritoneal 
washings.(4) Involvement of contralateral ovary and (5) Preservation of fertility. 
For accurate sampling the surgeon should indicate to the pathologist the presence 
and location of any adhesions.  
Methodical sampling of the omentum may reveal small implants not visible 
to the un-assisted eye that would influence staging and treatment. If the exact 
degree of malignancy cannot be established intra -operatively, these women may 
be best treated conservatively with more extensive surgery carried out after a 
thorough study of the removed neoplasms, omentum and peritoneal washings. 
This approach appears justified in view of a reported lower rate of malignant 
transformation than previously thought of. (53)             
 According to Russel et al(49)low malignant potential ovarian neoplasms 
represented 15% of all ovarian surface epithelial tumours. This correlates well 
with the observation of 16% of borderline cases in our study. Likewise the low 
malignant potential forms also occur at a younger age in the 3rd to 4th decade than 
frankly malignant neoplasms in the 4th to 5th decade in correlation with the 
literature. (53) 
 
In most series of studies by katsube et al, koonings et al and petterson et 
al,(26,27,41) mucinous borderline tumours are less common than serous borderline 
tumours but in our study mucinous borderline tumours out number the serous 
borderline tumours in close correlation with the studies by isarangkul in Thailand.  
In Japan and Norway, both  types of  tumours are equally prevalent.(44) 
As per the literature 42% of endometrioid tumours are associated with 
endometriosis in the same ovary or elsewhere in the pelvis.(14) In contrast in our 
study no such association has been found. 
Brenner tumours are often associated with other tumours such as mucinous 
cystadenoma, mature teratomas and transitional cell carcinoma of bladder.(14,31)  In 
our study one such association with mature cystic teratoma has been observed. 
In our study 7 cases of sexcord - stromal tumours have been observed. Of 
which granulosa cell tumor predominates  with 5 cases. One case of fibrothecoma 
and one case of fibroma with sarcomatous changes that typically has mitosis of 
more than 4/10 HPF, nuclear atypia and necrosis has also been observed . 
Germ cell tumours constitute a heterogeneous group of tumours reflecting 
the capacity for multiple lines of differentiation of the main stem cell system.  14 
cases of benign teratomas are observed in our study.  According to Hurwitz et 
al,age at presentation with malignant transformation in a dermoid cyst is older 
than those with benign disease and is more common in post menopausal 
women.(33)  In contrast in our study two cases of mature teratoma in post 
menopausal age group without any evidence of malignant transformation has been 
observed. 
 One case of dysgerminoma and 3 cases of mixed germ cell tumour with 
combination of (1) Dysgerminoma, Embryonal cell carcinoma (2) Yolk sac 
tumour, Embryonal cell  carcinoma and choriocarcinoma (3) Yolk sac and 
Embryonal cell carcinoma has been observed. 
Metastatic tumors to the ovary are common and occur in approximately 
30% of women dying of cancer.General features of ovarian metastasis include 
bilaterality, small multinodular surface tumours, extensive extra ovarian spread, 
unusual patterns of dissemination, unusual histological features, blood vessel and 
lymphatic invasion and a desmoplastic reaction.(44) 
                     Krukenberg tumour is the most common form of ovarian metastatic  
carcinoma in young women often found in fourth decade.(44)It is defined as  
ovarian neoplasms in which signet ring cells account for atleast 10% of the 
neoplasms. Mucin free epithelial cells, small glands with flattened lining cells, 
larger glands of typical intestinal and mucinous type, fibrous stroma ranging from 
densely cellular to edematous and extra cellular mucin may be prominent.(1,44)4 
cases of krukenberg tumour and one case of small cell- neuroendocrine tumour of 
intestinal origin (Fig-19) have been observed in our study. 
                         PAS (periodic acid schiff) stain is an extremely useful and 
esthetically pleasing technique.  Substances containing vicinal glycol groups or 
their amino or alkyl amino derivatives are oxidized by periodic acid to form 
dialdehydes, which combine with schiff reagent to form an insoluble magenta 
compound.This stain therefore demonstrates glycogen and neutral muco 
substances.(25) 
In  krukenberg tumors, intracellular material is PAS – positive, and diastase 
resistant.  Mucin pools are positive in mucinous carcinoma of ovary.(44) In our 
study, mucinous carcinoma of ovary shows PAS positive mucin pools, and 
krukenberg tumour, show  intracellular PAS positivity. 
                     The diffuse pattern of granulosa cell tumors may be confused with a 
benign thecoma, particularly when there is luteinization.  A reticulin stain is 
helpful, since granulosa cells typically grow in sheets or aggregates bound by 
reticulin fibrils, whereas thecomas contain an abundance of intercellular fibrils 
surrounding individual cells.  The distinction is important since granulosa cell 
tumors have an aggressive potential, whereas thecomas are with rare exceptions 
benign.(14) 
In this study, we applied reticulin stain for granulosa cell tumours and fibro 
thecoma.  The reticulin stain shows fibrils surrounding nests and larger aggregates 
of granulosa cells.  In  thecoma, reticulin stain highlights an investment of 
individual cells by fibrils. 
                  Expression of cytokeratin is present in all ovarian malignant tumours.  
Cytokeratins are a family of water insoluble, intracellular fibrous proteins present 
in almost all epithelia.  Keratin represent an excellent marker for epithelial 
differentiation regardless of whether the tumour is of endodermal, 
neuroectodermal, mesenchymal or germ cell derivation.(25)  
Antibodies to cytokeratin intermediate filament proteins have been used for 
many years to verify the epithelial origin of poorly differentiated carcinomas and 
to identify small volumes of tumor, often at matastatic sites including lymphnodes 
and meninges. More recently, the development of antibodies which react to 
specific cytokeratins in tissue that has been fixed in formalin and embedded in 
paraffin  has permitted investigations to examine the cytokeratin profile of lesions 
including benign and malignant tumours.(35) Undifferentiated and poorly 
differentiated serous carcinoma show positivity for cytokeratin.(39) In this study, 
poorly differentiated carcinomas showed focal  positivity. 
                The important immunohistochemical finding in adult granulosa cell 
tumours is the cytokeratin may be positive, typically with punctuate staining.(39) In 
this study, granulosa cell tumour showed the typical punctuate pattern of staining. 
              Dysgerminoma cells are,  typically immuno reactive for cytokeratin.(39,40)  
In this study dysgerminoma also showed focal positivity for cytokeratin.In yolksac  
tumour, the cytoplasm of tumour cells are immuno reactive for cytokeratin.  In our 
study, it did not show positivity.  In embryonal cell carcinoma, the cytoplasm of 
the tumour cells is typically immuno reactive for cytokeratin.(39)  In this study, in 
the mixed germ cell tumour, the embryonal cell component exhibited the focal 
positivity.                 Like wise, in choriocarcinoma, the syncytiotrophoblastic cells 
are typically immuno reactive with cytokeratin. Finally in this study, krukenberg 
tumours have shown diffuse positivity.      
           
   
 
CONCLUSION 
 
 
 
In the present prospective study of 132 ovarian neoplasms evaluated with 
clinical, histopathological, histochemistry and immunohistochemistry, the 
following conclusions are made and presented.  
 
1. The incidence of ovarian neoplasms  among the female neoplasms is 8.17%. 
 
2. Ovarian malignancy ranks second among the female genital tract malignancies. 
 
3. The ratio of benign and malignant ovarian neoplasm is 2.3:1. 
 
4. The  incidence of ovarian neoplasm is highest during the fifth decade followed 
by third decade. 
 
5. Eighty five percentage of ovarian tumours are unilateral in presentation, in 
which benign neoplasms are predominantly cystic, whereas malignancies are 
predominantly solid and cystic or purely solid. 
 6. Surface epithelial tumours are the most common neoplasm, of which serous 
cystadenoma is the commonest. 
7. Reticulin and PAS stain still have their value in the initial evaluation to 
distinguish Thecoma and Granulosa cell tumour as well as to demonstrate 
mucin filled signet ring cells in krukenberg tumour and mucinous nature of 
high grade mucinous cystadenocarcinoma.  
 
8. The  PANCYTOKERATIN exhibits varied pattern of positivity in various 
ovarian neoplasms.  
 
9. The epithelial immunohistochemical marker - PANCYTOKERATIN also 
exhibits focal positivity in non epithelial tumours like granulosa cell tumour, 
mixed germ cell tumour and metastatic tumours.  
 
 Advanced diagnostic tools and awareness of screening periodically 
for malignancies helps early detection of ovarian neoplasms and thereby reduces 
the morbidity and mortality. 
 
 
 
 
 
 
  
 
 
 
 
 
 
APPENDIX 
 
            I. HAEMATOXYLIN AND EOSIN 
 
Preparation of the solution: 
 
Distilled water                    - 1000 ml 
Ammonium alum               - 100 g 
Haematoxylin                     - 5 g 
Absolute Ethyl Alcohol      - 50 ml 
Mercuric Oxide                   - 2.5 g 
 
100 g of ammonium alum dissolved in 1000 ml of distilled water by heating and shaking 
at 60oC.Add solution of 50 g of haematoxylin in 50 ml of ethyl alcohol and bring rapidly 
to boil.When it begins to boil,remove from flame and add 2.5 g of Mercuric oxide.Mix by 
swirling gently. 
 
                                          EOSIN STAIN 
 
Eosin Y                              - 1 g 
Distilled water                   - 20 ml 
95% Ethanol                      - 80 ml 
Glacial acetic acid             - 0.2ml 
 
Dissolve 1 g eosin Y in 20 ml of water and add  95% ethanol and glacial acetic acid. 
 
Procedure: 
 
1.  Sections to water 
 
 2. Alum Hematoxylin (Harris) 
 
 3. Quick rinse in  water 
 
 4. Dehydration- 1% acid alcohol- 3 to 4 times 
 
 5. Rinse in tap water-30 seconds 
 
 6. Stain 1 % aqueous eosin Y for ¼  to 2 minutes 
 
 7. Wash in water 
 
8. Clear and mount  
 
                                         APPENDIX 
 
II. PER-IODIC ACID SCHIFF STAINING 
 
Preparation of solution: 
 
   Coleman’s Feulgen reagent: 
             
        Basic Fuchsin                        -  1.0 gm 
        Potassium metasulphite        -  2.0 gm 
        Normal Hydrochloric acid    -  10 cc 
        Distilled water                       -  200 cc 
        Activated carbon                   -  0.5 gm 
 
Dissolve 1.0 gm Basic Fuschin in 200 cc of hot distilled water.Bring to boiling 
point.Cool and add 2.0 gm potassium metabisulphite and 10 cc normal hydrochloric 
acid.Let bleach for 24 hrs. 
 
Add 0.5 gm of activated carbon,shake 1 mt and filter until colourless, store in 
refrigerator. 
 
1% Per-iodic Acid solution:  
 
Per-iodic Acid crystals                 -  1 gm 
Distilled water                              -  100 cc 
 
Normal Hydrochloric Acid solution: 
 
Hydrochloric Acid Conc sp.Gr 1.19  -83.5 cc 
Distilled water                                    -916.5 cc 
 
Procedure: 
 
1. Smear fixed in methanol for 20 mts 
2. Air dried 
3. Per-iodic acid for 10 mts(oxidant) 
4. Rinse in distilled water 
5.Place in Coleman’s Feulgen reagent (Schiff’s reagent) for 30 mts 
6.Wash in tap water for 10 mts for pink colour to develop 
7. Immerse in hematoxylin for 1 to 2 mts 
8. Rinse in tap water 
9. Differentiate in acid alcohol- 2 dips 
10. Wash in water 30 sec 
11.Two dips in ammonia water 2 % 
12. Wash in tap water- 30 sec 
13.Dehydrate in absolute alcohol 
14.Clear with xylene. 
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III RETICULIN STAINING 
 
 
Preparation of solution       
 
          1 % Pottasium permanganate. 
 
2 % Pottasium metasulphite. 
 
2 % Ferric Ammonium Sulphate. 
 
10 % Formalin neutral. 
 
0.2 % Gold chloride. 
 
2.5 % Sodium thio sulphate. 
 
10% KOH 
 
 
Ammoniacal silver solution. 
 
 
 
Preparation of Ammoniacal silver solution. 
 
 
10 % Ag No3 — 40 ml 
 
10 % KOH —10 ml 
 
• Add 40 ml of 10 % AgNo3 to 10 ml of 10 % KOH in a flask, cause 
silver to deposit. 
• Remove the supernant fluid. 
• Wash the deposit with distilled water several times. 
• Add strong ammonia drop by drop until the solution takes a faint 
sheen. 
• Make the solution to twice its volume by distilled water. 
 
Procedure 
 
 
• Section to water. 
• Oxidize in potassium permanganate-2 minutes. 
• Rince in water. 
• Decolorize in potassium meta bisulphate-1 minute. 
• Prolonged wash in water-5 minutes. 
• Sensitise in ferric ammonium sulphate-1 minute. 
• Prolonged wash in tape water followed by 2 changes of distilled water. 
• Impregnate in ammoniacal silver solution – 1 minute 
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        IV - IMMUNO HISTOCHEMISTRY 
 
 
Procedure 
 
1. 5 microns thick sections were cut from the blocks received on slides coated with     
chrome alum gelatin. 
2. Slides were dewaxed and dehydrated in graded alcohol. 
3. Slides were immersed in 0.3 % Hydrogen peroxide for 20 minutes to block 
endogenous peroxidase activity. 
4. Washed in phosphate buffered saline (PBS) 
5. Incubated in primary antibody & Ki – 67. 
6. Washed in PBS. 
7. Biotinylated link was applied for 20 minutes. 
8. Washed in PBS. 
9. Incubated in streptavidin-biotin complex. 
10. Washed in PBS 
11. DAB was used as chromogen. 
12. Washed and  can be stained with haematoxylin. 
13. Mounted with coverslip. 
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 MASTER CHART 
S.No HPE.NO. AGE YEARS IP NO
CLINICAL 
PRESENTATION GROSS 
1.  G 238/06 30 6255 MASS ABDOMEN UNILATERAL, CYSTIC BENIGN S
2.  G 239/06 42 1943 MASS ABDOMEN UNILATERAL, VARIEGATED 
SEROUS C
POORLY D
3.  G 253/06 20 5214 MASS ABDOMEN UNILATERAL, CYSTIC BENIGN M
4.  G 257/06 25 6256 PAIN/MASS ABDOMEN UNILATERAL, VARIEGATED 
MIXED GE
(DYSGERM
CARCINOM
5.  G 299/06 30 7188 MASS ABDOMEN UNILATERAL, CYSTIC MATURE T
6.  G 327/06 28 7567 MASS ABDOMEN UNILATERAL, CYSTIC BENIGN M
7.  G 338/06 33 9288 PREGNANCY ASSOCIATED UNILATERAL, CYSTIC DERMOID
8.  G 359/06 56 7834 ASCITES BILATERAL VARIEGATED ENDOMET
9.  G 398/06 25 10409 MASS ABDOMEN UNILATERAL, CYSTIC SIMPLE SE
10.  G 418/06 55 8545 MASS ABDOMEN UNILATERAL, CYSTIC BENIGN M
11.  G 423/06 40 6684 PAIN/MASS ABDOMEN UNILATERAL, CYSTIC SIMPLE SE
12.  G 445/06 27 12515 PREGNANCY ASSOCIATED UNILATERAL, CYSTIC SIMPLE SE
13.  G 446/06 65 4358 MASS ABDOMEN UNILATERAL, CYSTIC ENDOMET
14.  G 447/06 40 8804 MASS WITH ASCITES UNILATERAL, VARIEGATED 
PAPILLAR
CYSTADEN
15.  G 473/06 22 11794 PAIN ABDOMEN UNILATERAL, SOLID AND CYSTIC BENIGN S
16.  G 480/06 24 10445 PAIN MASS ABDOMEN UNILATERAL, CYSTIC BENIGN S
17.  G 495/06 25 13735 MASS ABDOMEN UNILATERAL, CYSTIC BENIGN  M
18.  G 505/06 16 14426 MASS ABDOMEN UNILATERAL, CYSTIC SEROUS C
19.  G 516/06 40 10831 MASS ABDOMEN UNILATERAL - SOLID & CYSTIC FIBRO THE
20.  G 625/06 50 17639 MASS AND PAIN UNILATERAL - CYSTIC &  SOLID     SEROUS C
21.  G 658/06 35 PRIVATE MASS ABDOMEN UNILATERAL, CYSTIC BENIGN S
22.  G 692/06 33 21957 ACUTE PAIN ABDOMEN 
BILATERAL - SOLID WITH 
FEW CYSTIC BILATERA
23.  G 714 06 42 22236 MASS ABDOMEN BILATERAL VARIEGATED PAPILLARCYSTADEN
24.  G 807/06 14 24869 PAIN ABDOMEN UNILATERAL - CYSTIC  SIMPLE SE
25.  G 818/06 70 23481 MASS ABDOMEN UNILATERAL, VARIEGATED 
SEROUS P
CYSTADEN
26.  G 908/06 60 26073 MASS ABDOMEN BILATERAL - CYSTIC BENIGN MSEROUS C
27.  G 937/06 45 5685 MASS ABDOMEN UNILATERAL - CYSTIC  BENIGN D
28.  G 973/06 55 28278 MASS ABDOMEN ASCITES 
BILATERAL - SOLID AND 
CYSTIC 
HIGH GRA
SEROUS C
29.  G 997/06 25 30757 PAIN AND MASS UNILATERAL - CYSTIC MUCINOU
ABDOMEN WITH SOLID 
30.  G 1018/06 36 306836 MASS ABDOMEN UNILATERAL - CYSTIC  TORSION 
31.  G 1086/06 45 30268 MASS ABDOMEN UNILATERAL - CYSTIC  SEROUS PCYSTADEN
32.  G 1100/06 40 29628 PAIN ABDOMEN UNILATERAL - CYSTIC  SEROUS TMALIGNA
33.  G 1114/06 45 29905 MASS ABDOMEN BILATERAL - SOLID & CYSTIC MUCINOU
34.  G 1119/06 45 31556 MASS ABDOMEN UNILATERAL, VARIEGATED SEROUS C
35.  G 1169/06 40 30556 MASS ABDOMEN UNILATERAL - SOLID & CYSTIC SEROUS C
36.  G 1191/06 42 306893 PAIN /BLEEDING UNILATERAL, VARIEGATED 
SEROUS P
CYSTADEN
GRADE 
37.  G 1120/06 27 35047 MASS ABDOMEN UNILATERAL - CYSTIC     MUCINOU
38.  G 1137/06 25 36047 MASS ABDOMEN UNILATERAL - CYSTIC  SIMPLE SE
39.  G 1176/06 18 35663   BLEEDING  PER     VAGINUM UNILATERAL - CYSTIC  DERMOID
40.  G 1341/06 19 40875 PREGNANCY  UNILATERAL - CYSTIC  SEROUS C
41.  G 1344/06 45 37067 MASS ABDOMEN UNILATERAL - CYSTIC  MUCINOU
42.  G 1374/06 39 307372 MASS & PAIN ABDOMEN UNILATERAL - CYSTIC  ENDOMET
43.  G 1392/06 40 307376 MASS ABDOMEN UNILATERAL - CYSTIC  SEROUS C
44.  G 1425/06 23 44545    MASS ABDOMEN    UNILATERAL - CYSTIC     ENDOMET
45.  G 1446/06 47 38875 PAIN ABDOMEN UNILATERAL - CYSTIC  SEROUS C
46.  G 1449/06 25 44098 MASS  ABDOMEN UNILATERAL - CYSTIC  MUCINOU
47.  G 1481/06 30 44099 MASS  ABDOMEN UNILATERAL - CYSTIC  MUCINOU
48.  G 1553/06 40 45799 MASS  ABDOMEN BILATERAL - CYSTIC MUCINOU
49.  G 1543/06 18 49038 PREGNANCY  UNILATERAL - CYSTIC  TERATOM
50.  G 1604/06 36 48263 MASS  ABDOMEN BILATERAL - CYSTIC   MUCINOU   MALIGNA
51.  G 1613/06 40 48143 MASS ABDOMEN UNILATERAL - CYSTIC     MUCINOUMALIGNA
52.  G 1625/06 35 47738 MASS ABDOMEN  UNILATERAL, VARIEGATED 
GRANULO
TYPE 
53.  G 1641/06 27 51135 PREGNANCY UNILATERAL - CYSTIC  DERMOID
54.  G 1651/06 33 48734 MASS WITH PAIN UNILATERAL - CYSTIC  BENIGN S
55.  G 1673/06 35 43529 MASS  ABDOMEN UNILATERAL - CYSTIC  SEROUS TMALIGNA
56.  693/06  52 878752 MASS WITH ASCITES    BILATERAL SOLID 
SMALL CE
CARCINOM
57.  930/06 45 880075 MASS ABDOMEN UNILATERAL - SOLID & CYSTIC SEROUS C
58.  1245/06 60 885325 MASS  ABDOMEN BILATERAL CYSTIC 
A) ONE OV
SEROUS  C
CYSTADEN
59.  1999/06 22 90442 MASS ABDOMEN UNILATERAL - CYSTIC  BENIGN SER
60.  2018/06 20 903077 BLEEDING PER VAGINUM UNILATERAL - SOLID DYSGERM
61.  2122/06 36 903647 MASS ABDOMEN UNILATERAL - SOLID ENDOMET
62.  2719/06 11 38466 MASS ABDOMEN UNILATERAL - CYSTIC  MATURE C
63.  2969/06 45 38595 MASS ABDOMEN UNILATERAL - CYSTIC  BENIGN M
64.  3048/06 57 917599 ACUTE ABDOMEN UNILATERAL - CYSTIC  MUCINOU
65.  3169/06 55 915265 MASS ABDOMEN UNILATERAL, VARIEGATED 
FIBROMA 
TRANS-- F
66.  G 19/07 49 48143 MASS ABDOMEN UNILATERAL - CYSTIC  SIMPLE SE
67.  G 66/07 25 307396 MASS ABDOMEN UNILATERAL - CYSTIC  MATURE C
68.  G 110/07 40 1565 MASS ABDOMEN UNILATERAL - CYSTIC  BENIGN M
69.  G 117/07 40 2718 MASS  ABDOMEN UNILATERAL - CYSTIC  BENIGN S
70.  G 122/07 40 2266 MASS ABDOMEN UNILATERAL - CYSTIC  MATURE C
71.  G 144/07 50 52279 MASS & ASCITES UNILATERAL - SOLID ADULT GR
72.  G 165/07 47 5056 MASS & ASCITES BILATERAL - VARIEGATED 
B/L PAPIL
CARCINOM
73.  G 174/07 30 30874 MASS ABDOMEN UNILATERAL - CYSTIC  BENIGN M
74.  G 238/07 57 35995 MASS ABDOMEN UNILATERAL - VARIEGATED 
PAPILLAR
CYSTDEN
75.  G 313/07 28 9215 MASS ABDOMEN UNILATERAL - CYSTIC  BORDERLCYSTADEN
76.  G 329/07 55 15273 MASS ABDOMEN BILATERAL - VARIEGATED 
PAPILLAR
CYSTADEN
77.  G 333/07 30 7690 MASS ABDOMEN BILATERAL -SOLID BILATERA
78.  G 334/07 14 6690 MASS ABDOMEN UNILATERAL - CYSTIC  MATURE  
79.  G 342/07 25 9960 PREGNANCY  UNILATERAL - CYSTIC  SEROUS C
80.  G 377/07 18 9955 MASS ABDOMEN UNILATERAL - CYSTIC  MATURE  
81.  G 438/07 34 8433 PAIN ABDOMEN UNILATERAL - CYSTIC  BENIGN M
82.  G 449/07 23 10579 MASS ABDOMEN UNILATERAL - CYSTIC  BENIGN M
83.  G 453/07 46 5558 MASS & ASCITES UNILATERAL - CYSTIC    MUCINOUMALIGNAN
84.  G 462/07 62 9886 MASS & ASCITES BILATERAL - SOLID HIGH GRACYSTDEN
85.  35/07 58 922616 MASS & ASCITES UNILATERAL - CYSTIC & SOLID 
MATURE T
WITH BRE
86.  307/07 45 928123 MASS ABDOMEN UNILATERAL - CYSTIC  BENIGN M
87.  G 539/07 50 13303 MASS ABDOMEN UNILATERAL - CYSTIC  BENIGN M
88.  1362/07 40 944066 MASS ABDOMEN  BILATERAL VARIEGATED BILATERA
89.  G 426/07 46 9096 MASS & ASCITES BILATERAL - CYSTIC 
a. ONE O
CYSTA
b. OTHER
TUMO
MALIG
90.  G 680/07 43 12911 MASS ABDOMEN UNILATERAL - CYSTIC    MUCINOUMALIGNAC
91.  G 748/07 40 20023 MASS ABDOMEN UNILATERAL - CYSTIC  BENIGN C
92.  G 829/07 40 22214 MASS ABDOMEN UNILATERAL - CYSTIC  MATURE T
93.  G 841/07 38 22751 MASS  ABDOMEN UNILATERAL - CYSTIC  BENIGN M
94.  G 881/07 53 233328 MASS  ABDOMEN UNILATERAL - CYSTIC  MUCINOUMALIGNA
95.  G 872/07 57 13353 MASS ABDOMEN UNILATERAL - VARIEGATED GRANULO
96.  G 890/07 38 22240 MASS ABDOMEN BILATERAL - SOLID & CYSTIC 
SEROUS T
MALIGNA
97.  G 960/07 12 27245 MASS ABDOMEN BILATERAL - CYSTIC & SOLID 
MIXED GE
(YOLKSAC
NOM )  
98.  G 1000/07 22 10375 MASS ABDOMEN UNILATERAL - CYSTIC & SOLID MUCINOU
99.  G 1002/07 27 30196 MASS ABDOMEN UNILATERAL - CYSTIC  MATURE -
100. G 1047/07 48 32291   MASS ABDOMEN UNILATERAL - CYSTIC  BENIGN  SE
101. G 1088/07 55 33624 MASS ABDOMEN UNILATERAL - CYSTIC  BENIGN M
102. G 1268/07 50 33625 MASS ABDOMEN UNILATERAL - CYSTIC   SEROUS MALIGNA
103. G 1279/07 45 37375 MASS  ABDOMEN UNILATERAL - CYSTIC & SOLID MUCINOU
104. G 1302/07 35 311914 PAIN ABDOMEN UNILATERAL - CYSTIC  BENIGN S
105. G 1316/07 55 33431    MASS ABDOMEN BILATERAL - VARIEGATED  BILATERA
106. G 1317/07 41 40230 MASS ABDOMEN UNILATERAL - CYSTIC  SEROUS  TMALIGNA
107. G 1334/07 40 41060 MASS ABDOMEN BILATERAL - SOLID, CYSTIC, VARIEGATED 
BILATERA
CARCINOM
108. G 1356/07 20 43054 MASS ABDOMEN UNILATERAL - CYSTIC  BENIGN S
109. G 1377/07 42 311944 MASS ABDOMEN UNILATERAL - CYSTIC  BENIGN MCYSTADEN
110. G 1382/07 35 311945 MASS ABDOMEN UNILATERAL - CYSTIC  BENIGN S
111. G 1387/07 50 43658 MASS ABDOMEN UNILATERAL - CYSTIC  BENIGN S
112. G 1405/07 23 311958 MASS ABDOMEN UNILATERAL - CYSTIC  BENIGN PACYSTADEN
113. G 1415/07 21 46606 MASS ABDOMEN UNILATERAL - VARIEGATED 
 
JUVENILE
 
 
114. G 1422/07 22 42939 MASS ABDOMEN BILATERAL – CYSTIC 
 
BILATERAL – CYSTIC 
RIGHT OV
CYSTADEN
LEFT OVA
BORDERL
115. G 1438/07 48 46215 MASS ABDOMEN UNILATERAL - CYSTIC  BENIGN M
116. G 1439/07 50 311984 MASS ABDOMEN BILATERAL – SOLID BILATERA
117. G 1480/07 27 47880 PAIN ABDOMEN UNILATERAL - CYSTIC  BENIGN S
118. G 1494/07 40 51573 MASS ABDOMEN  UNILATERAL - CYSTIC  BENIGN SFIBROMA
119. G 31/08 27 1043 MASS ABDOMEN UNILATERAL - CYSTIC  BENIGN S
120. G 97/08 24 4640 MASS ABDOMEN UNILATERAL - CYSTIC  SEROUS TMALIGNA
121. G 103/08 35 3480 MASS ABDOMEN   UNILATERAL - CYSTIC  MUCINOUMALIGNA
122. G 316/08 35 927735 MASS ABDOMEN UNILATERAL - CYSTIC   MUCINOUMALIGNA
123. G 91/08 48 4075 MASS ABDOMEN UNILATERAL - CYSTIC & SOLID 
GRANULO
TUMOUR
124. G 127/08 21 5860 MASS ABDOMEN UNILATERAL - CYSTIC  BENIGN M
125. G 153/08 36 6570 MASS ABDOMEN UNILATERAL - CYSTIC  BENIGN M
126. G 179/08 27 9395 MASS ABDOMEN UNILATERAL - CYSTIC  BENIGN M
127. G 187/07 57 8647 PAIN ABDOMEN UNILATERAL - CYSTIC  BENIGN M
128. G 221/08 19 9148 MASS,  PRIMARY AMANNORRHOEA UNILATERAL - SOLID GONADOB
129. 567/08 19 203108 MASS ABDOMEN UNILATERAL - SLIDE FOR REVIEW 
MIXED GE
(YOLK SA
COMPONE
130. G 248/08 40 11460 MASS ABDOMEN UNILATERAL - CYSTIC  MATURE –
131. G 242/08 48 924 MASS ABDOMEN UNILATERAL - VARIEGATED 
PAPILLAR
CYSTADEN
132. G 274/08 22 313989 PREGNANCY ASSOCIATED UNILATERAL - CYSTIC  
MUCINOU
MALIGNA
 
 
